CSIMarket
 


Celgene Corp  (CELG)
Other Ticker:  
 
 

CELG's Revenue Growth by Quarter and Year

Celgene's Revenue results by quarter and year




CELG Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - 4,037.00 3,483.00 2,980.50
III Quarter September 4,520.00 3,892.00 3,287.00 2,982.80
II Quarter June 4,400.00 3,814.00 3,268.00 2,754.30
I Quarter March 4,025.00 3,538.00 2,960.00 2,511.60
FY   12,945.00 15,281.00 12,998.00 11,229.20



CELG Revenue third quarter 2019 Y/Y Growth Comment
Celgene Corp reported Revenue increase of 16.14% year on year in the third quarter, to $ 4,520.00 millions, this is lower than Celgene Corp's recent average Revenue improvement of 30.14%.

Looking into third quarter results within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue growth. While Celgene Corp' s Revenue growth of 16.14% ranks overall at the positon no. 1003 in the third quarter.




CELG Revenue ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - 15.91 % 16.86 % 16.28 %
III Quarter September 16.14 % 18.41 % 10.2 % 27.79 %
II Quarter June 15.36 % 16.71 % 18.65 % 20.92 %
I Quarter March 13.76 % 19.53 % 17.85 % 20.7 %
FY   - 17.56 % 15.75 % 21.32 %

Financial Statements
Celgene's third quarter 2019 Revenue $ 4,520.00 millions CELG's Income Statement
Celgene's third quarter 2018 Revenue $ 3,892.00 millions Quarterly CELG's Income Statement
New: More CELG's historic Revenue Growth >>


CELG Revenue (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - 3.73 % 5.96 % -0.08 %
III Quarter September 2.73 % 2.05 % 0.58 % 8.3 %
II Quarter June 9.32 % 7.8 % 10.41 % 9.66 %
I Quarter March -0.3 % 1.58 % -0.69 % -2.02 %
FY (Year on Year)   - 17.56 % 15.75 % 21.32 %




Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #226
Overall #1003

Revenue Y/Y Growth Statistics
High Average Low
89.06 % 30.14 % 10.01 %
(Sep. 30, 2006)   (June 30. 2009)
Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #226
Overall #1003
Revenue Y/Y Growth Statistics
High Average Low
89.06 % 30.14 % 10.01 %
(Sep. 30, 2006)   (June 30. 2009)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Celgene's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
29.63 % 6.81 % -11.12 %
(June 30. 2005)   (Sep. 30, 2005)


CELG's III. Quarter Q/Q Revenue Comment
Celgene Corp achieved in the III. Quarter 2019 below company average Revenue growth of 2.73% quarter on quarter, to $ 4,520.00 millions.

Even if the III. Quarter 2019 results were lower than the ordinary of 6.81 %, this has been still encouraging news, as the III. Quarter expension, transcends the 2.05% Revenue rise in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue quarter on quarter growth. While Celgene's Revenue growth quarter on quarter, overall rank is 1700.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #267
Overall #1700
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #267
Overall #1700
Revenue Q/Q Growth Statistics
High Average Low
29.63 % 6.81 % -11.12 %
(June 30. 2005)   (Sep. 30, 2005)


CELG's III. Quarter Q/Q Revenue Comment
Celgene Corp achieved in the III. Quarter 2019 below company average Revenue growth of 2.73% quarter on quarter, to $ 4,520.00 millions.

Although the III. Quarter 2019 performance was below the ordinary , that has been yet promising news, as the III. Quarter improvement, outshines the 2.05% rise in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue quarter on quarter growth. While Celgene's Revenue growth quarter on quarter, overall rank is 1700.


Celgene's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
Cumulative Revenue 12 Months Ending $ 16,982.00 $ 16,354.00 $ 15,768.00 $ -8,584.00 $ 14,727.00
Y / Y Revenue Growth (TTM) 15.31 % 15.81 % 16.15 % - 17.86 %
Year on Year Revenue Growth Overall Ranking # 1004 # 1019 # 1013 # 0 # 1022
Seqeuential Revenue Change (TTM) 3.84 % 3.72 % 3.19 % - 4.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 1007 # 1024 # 1005 # 1007 # 1159




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, Celgene's cumulative twelve months Revenue were $ 16,982 millions, company would post below average annual Revenue growth of 4.28% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the Celgene's Revenue growth from the 4400% growth in Jun 30 2019.

In the Healthcare sector 200 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1004, from total ranking in previous quarter at 1019.

Revenue TTM Q/Q Growth Statistics
High Average Low
17.53 %
5.91 %
-24.75 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 201
Overall # 1004

Revenue TTM Y/Y Growth Statistics
High Average Low
80.99 %
31.73 %
3.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 215
S&P 500 # 1007
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, Celgene's cumulative twelve months Revenue were $ 16,982 millions, company would post below average annual Revenue growth of 3.88% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the Celgene's Revenue growth from the 4400% growth in Jun 30 2019.

In the Healthcare sector 200 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1004, from total ranking in previous quarter at 1019.

Revenue TTM Q/Q Growth Statistics
High Average Low
17.53 %
5.91 %
-24.75 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 201
Overall # 1004

Revenue TTM Y/Y Growth Statistics
High Average Low
80.99 %
31.73 %
3.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 215
S&P 500 # 1007




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CELG's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CELG's Competitors
Revenue Growth for Celgene's Suppliers
Revenue Growth for CELG's Customers

You may also want to know
CELG's Annual Growth Rates CELG's Profitability Ratios CELG's Asset Turnover Ratio CELG's Dividend Growth
CELG's Roe CELG's Valuation Ratios CELG's Financial Strength Ratios CELG's Dividend Payout Ratio
CELG's Roa CELG's Inventory Turnover Ratio CELG's Growth Rates CELG's Dividend Comparisons



Companies with similar Revenue growth for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2019
Cyclo Therapeutics Inc 27.37%$ 27.367 millions
Insulet Corporation27.16%$ 27.164 millions
Alphatec Holdings Inc 26.95%$ 26.950 millions
Corcept Therapeutics Inc26.47%$ 26.472 millions
Sarepta Therapeutics Inc 26.19%$ 26.189 millions
Axogen inc 26.05%$ 26.054 millions
Seagen Inc 25.88%$ 25.875 millions
Quotient Limited25.60%$ 25.596 millions
Pacira Biosciences inc 25.45%$ 25.449 millions
Lifemd Inc 25.30%$ 25.298 millions
Axon Enterprise inc 24.80%$ 24.802 millions
Penumbra Inc24.77%$ 24.771 millions
Biolife Solutions Inc24.77%$ 24.767 millions
Teladoc Health inc 24.34%$ 24.339 millions
Addus Homecare Corporation23.38%$ 23.376 millions
Regeneron Pharmaceuticals Inc 23.14%$ 23.138 millions
Alexion Pharmaceuticals Inc 23.05%$ 23.049 millions
Staar Surgical Co22.93%$ 22.930 millions
Incyte Corp22.66%$ 22.660 millions
Intuitive Surgical Inc 22.51%$ 22.511 millions
Cumberland Pharmaceuticals Inc22.13%$ 22.130 millions
Inspiremd Inc 22.11%$ 22.107 millions
Biocryst Pharmaceuticals Inc22.08%$ 22.077 millions
Vertex Pharmaceuticals Inc21.07%$ 21.069 millions
Vanda Pharmaceuticals Inc 21.06%$ 21.064 millions
Surgepays Inc 21.00%$ 21.003 millions
Pacific Biosciences Of California Inc 20.68%$ 20.677 millions
Edwards Lifesciences Corporation20.67%$ 20.671 millions
Medpace Holdings inc 20.63%$ 20.633 millions
Exelixis Inc 20.54%$ 20.544 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BHVN's Profile

Stock Price

BHVN's Financials

Business Description

Fundamentals

Charts & Quotes

BHVN's News

Suppliers

BHVN's Competitors

Customers & Markets

Economic Indicators

BHVN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071